NeuroBB Co., Ltd. is a biotechnology company developing next-generation oral therapeutics for Alzheimer’s disease. The company combines its small-molecule drug development expertise with NeuroADMET, an AI-based drug candidate evaluation platform, to support the comprehensive assessment of efficacy, safety, and drug-like properties and facilitate data-driven decision-making throughout drug development.

NeuroBB’s lead pipeline, NBB-116, is an orally available small-molecule drug candidate for Alzheimer’s disease and is currently undergoing preclinical development. Building on its drug development capabilities and NeuroADMET platform, NeuroBB is advancing NBB-116 toward further development and pursuing global licensing and co-development opportunities with pharmaceutical and biotechnology partners.